Ignite Creation Date:
2024-05-06 @ 6:46 PM
Last Modification Date:
2024-10-26 @ 2:54 PM
Study NCT ID:
NCT05780736
Status:
TERMINATED
Last Update Posted:
2024-07-12
First Post:
2023-02-24
Brief Title:
A Study to Evaluate Nivolumab in the Treatment of Early Stage Esophageal or Gastroesophageal Cancer
Sponsor:
Bristol-Myers Squibb
Organization:
Bristol-Myers Squibb
Study Overview
Official Title:
Prospective Evaluation of Nivolumab in Adjuvant Esophageal CarcinomaGastroesophageal Junction Carcinoma A Non-interventional Study
Status:
TERMINATED
Status Verified Date:
2024-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
A decision was made to terminate the study due to expected timelines associated with start-up participant enrollment ethics committee approval and data availability from the study
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
PROSPECT-ESO
Brief Summary:
The purpose of this study is to describe the effectiveness and use of nivolumab after surgery in participants with early stage Stage IIIII Esophageal CancerGastroesophageal Junction Cancer ECGEJC
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None